Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 15/20 | 0.51 |
| ▸ | CHRM4 | P08173 | 15/20 | 0.51 |
| ▸ | CHRM5 | P08912 | 15/20 | 0.51 |
| ▸ | CHRM1 | P11229 | 15/20 | 0.51 |
| ▸ | CHRM3 | P20309 | 15/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7641420 | 0.89 | CHRM2 (0.40) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL7640098 | 0.86 | CHRM2 (0.39) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL7638346 | 0.86 | GAA (0.44) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL7641399 | 0.85 | ALDH1A1 (0.40) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL7636519 | 0.84 | CHRM2 (0.47) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL7639398 | 0.84 | ALDH1A1 (0.39) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL7633650 | 0.82 | MAPT (0.47) | RAB9AKMT2A | |
| SCHEMBL7642699 | 0.81 | KDM4E (0.43) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL7639378 | 0.76 | CHRM2 (0.52) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL7642329 | 0.74 | ALDH1A1 (0.36) | CHRM2CHRM4CHRM5CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6340772-B2 | AROMATIZATION OF CYCLOHEXENONE DERIVATIVES VIA (CHLORO)CYCLOHEXADIENE | NIPPON KAYAKU CO., LTD. (JP) | 2002-01-22 | — | — | US | disclosed |
| US-20010020112-A1 | Process for preparing (hetero) aromatic substituted benzene derivatives | TOYA TETSUYA (JP) | 2001-09-06 | — | — | US | disclosed |
| US-6271418-B1 | AROMATIZATION OF CYCLOHEXENONE DERIVATIVES VIA (CHLORO)CYCLOHEXADIENE DERIVATIVES. | NIPPON KAYAKU CO., LTD. (JP) | 2001-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010020112-A1 | Process for preparing (hetero) aromatic substituted benzene derivatives | AHR, CYP3A4, CYP4B1 | CHRM2 3042/4885CHRM4 2453/4885CHRM5 3232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.